As of November 7, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Senti Biosciences Holdings, Inc. The largest reported stake is Celadon Partners SPV 24's, at 54.6%. 7 filings are on record since September 2, 2025 (Schedule 13D/A, September 11, 2026).
Sell to companies like Senti Biosciences Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Celadon Partners SPV 24 · Sole voting: 0 · Shared voting: 25,748,890 · Sole dispositive: 0 · Shared dispositive: 25,748,890 · SCHEDULE 13D/A, 2026-09-11
- · Holder: Celadon Partners SPV 24 · Percent: 54.6% · SCHEDULE 13D/A
- · Holder: Celadon Partners SPV 24 · Percent: 54.6% · SCHEDULE 13D/A
- · Holder: Bayer HealthCare LLC · Percent: 17.82% · SCHEDULE 13D/A
- · Holder: New Enterprise Associates 15, L.P. · Percent: 12.1% · SCHEDULE 13D/A
Senti Biosciences Holdings, Inc. has 7 Schedule 13D or 13G filings on record since 2025-09-02. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Celadon Partners SPV 24 | 54.6% | 25,748,890 | SCHEDULE 13D/A, 2026-09-11 | 2026-09-03 |
| Bayer HealthCare LLC | 17.82% | 6,142,848 | SCHEDULE 13D/A, 2026-04-16 | 2026-03-27 |
| New Enterprise Associates 15, L.P. | 12.1% | 3,775,615 | SCHEDULE 13D/A, 2026-03-31 | 2026-03-27 |
Holding shares or following this stake? See who's behind Senti Biosciences Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Senti Biosciences Holdings, Inc. and the records around it.
Senti Biosciences Holdings, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- New Enterprise Associates 15, L.P. also filed stake reports on 1 other company: Arcellx, Inc. (Apr 2026)
Watch Senti Biosciences Holdings, Inc.
Get an email when Senti Biosciences Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Senti Biosciences Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Senti Biosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Senti Biosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Celadon Partners SPV 24 | 0 | 25,748,890 | 0 | 25,748,890 | SCHEDULE 13D/A, 2026-09-11 |
| Celadon Partners, LLC | 0 | 25,748,890 | 0 | 25,748,890 | SCHEDULE 13D/A, 2026-09-11 |
| CPIF II-7 Limited | 0 | 25,748,890 | 0 | 25,748,890 | SCHEDULE 13D/A, 2026-09-11 |
The latest filing identifies Senti Biosciences Holdings, Inc. by CUSIP 816944102 and gives its principal executive office as 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13D/A, 2026-09-11).
Source of funds (Item 3)
On September 3, 2026, the Issuer entered into an equity commitment letter (the "Equity Commitment Letter") with CPIF II-9 Limited (the "Investor"), an entity affiliated with Celadon Partners SPV 24. Pursuant to the Equity Commitment Letter, the Investor commits to purchase, or to cause one or more of its affiliates to purchase, newly issued shares of Common Stock, for an aggregate purchase price equal to $2,500,000 (the "Commitment"; such amount, the "Commitment Amount"), at a per share price equal to the "Minimum Price" as defined in Nasdaq Listing Rule 5635(d) (the "Per Share Price").Celadon Partners SPV 24, SCHEDULE 13D/A, 2026-09-11
Purpose of Transaction (Item 4)
Celadon Partners SPV 24
The Issuer plans to use substantially all of the proceeds from the sale of shares of Common Stock pursuant to the Equity Commitment Letter to support its business following completion of the Merger.Item 4 of the SCHEDULE 13D/A filed 2026-09-11
New Enterprise Associates 15, L.P.
NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-31; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-02 | Celadon Partners SPV 24 | 45% | SCHEDULE 13D/A |
| 2026-01-20 | Celadon Partners SPV 24 | 45% | SCHEDULE 13D/A |
| 2026-03-31 | New Enterprise Associates 15, L.P. | 12.1% | SCHEDULE 13D/A |
| 2026-04-16 | Bayer HealthCare LLC | 17.82% | SCHEDULE 13D/A |
| 2026-05-04 | Celadon Partners SPV 24 | 54.6% | SCHEDULE 13D/A |
| 2026-07-16 | Celadon Partners SPV 24 | 54.6% | SCHEDULE 13D/A |
| 2026-09-11 | Celadon Partners SPV 24 | 54.6% | SCHEDULE 13D/A |
Questions about who owns Senti Biosciences Holdings, Inc.
Who owns Senti Biosciences Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Senti Biosciences Holdings, Inc.: Celadon Partners SPV 24 (54.6%, Schedule 13D/A, filed 2026-09-11), Bayer HealthCare LLC (17.82%, Schedule 13D/A, filed 2026-04-16) and New Enterprise Associates 15, L.P. (12.1%, Schedule 13D/A, filed 2026-03-31).
Who are the largest shareholders of Senti Biosciences Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Senti Biosciences Holdings, Inc. on this page are Celadon Partners SPV 24 (54.6%), Bayer HealthCare LLC (17.82%) and New Enterprise Associates 15, L.P. (12.1%).
When did Celadon Partners SPV 24 buy into Senti Biosciences Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Celadon Partners SPV 24 on this page is the Schedule 13D/A, filed 2025-09-02, reporting 45%; its latest, Schedule 13D/A filed 2026-09-11, reports 54.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Senti Biosciences Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Leadership change: Edward Mathers departs | — | Leadership changes | Source |
| September 24, 2026 | Leadership change: Brenda Cooperstone departs | — | Leadership changes | Source |
| June 4, 2026 | Form D, private offering | $10M sold | Form D page | Source |
| December 19, 2024 | Form D, private offering | $37.60M sold | Form D page | Source |
Senti Biosciences Holdings, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Senti Biosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.